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Abstract
Background: Management of influenza, a major contributor to the worldwide disease burden, is complicated by lack of
reliable methods for early identification of susceptible individuals. Identification of molecular markers that can augment
existing diagnostic tools for prediction of severity can be expected to greatly improve disease management capabilities.
Methodology/Principal Findings: We have analyzed cytokines, proteome flux and protein adducts in bronchoalveolar
lavage (BAL) and sera from mice infected with influenza A virus (PR8 strain) using a previously established non-lethal model
of influenza infection. Through detailed cytokine and protein adduct measurements of murine BAL, we first established the
temporal profile of innate and adaptive responses as well as macrophage and neutrophil activities in response to influenza
infection. A similar analysis was also performed with sera from a longitudinal cohort of influenza patients. We then used an
iTRAQ-based, comparative serum proteome analysis to catalog the proteome flux in the murine BAL during the stages
correlating with ‘‘peak viremia,’’ ‘‘inflammatory damage,’’ as well as the ‘‘recovery phase.’’ In addition to activation of acute
phase responses, a distinct class of lung proteins including surfactant proteins was found to be depleted from the BAL
coincident with their ‘‘appearance’’ in the serum, presumably due to leakage of the protein following loss of the integrity of
the lung/epithelial barrier. Serum levels of at least two of these proteins were elevated in influenza patients during the
febrile phase of infection compared to healthy controls or to the same patients at convalescence.
Conclusions/Significance: The findings from this study provide a molecular description of disease progression in a mouse
model of influenza and demonstrate its potential for translation into a novel class of markers for measurement of acute lung
injury and improved case management.
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Introduction
Influenza virus infections result in a contagious respiratory
illness with highly varied outcomes among the human populations.
While a significant proportion of the populations worldwide
recover from influenza within 2 weeks, susceptible individuals can
have a variety of severe and potentially lethal complications
including pneumonia, bronchitis and acute respiratory distress
syndrome (ARDS). Despite the development of vaccines and
therapeutics, influenza epidemics continue to pose a major
challenge to worldwide disease management efforts due to periodic
emergence of drug-resistant influenza strains or new strains to
which pre-existing immunity is low or absent. One example is the
pandemic influenza H1N1 swine flu strain which is circulating
worldwide since its emergence in 2009 and causes illnesses similar
to the seasonal H3N2 influenza strains [1].
The most common symptoms of influenza include fever, runny
nose, sore throat, cough, lethargy but occasionally more severe
respiratory complications are reported which could be lethal
without early detection and treatment. While some of the risk
factors that trigger severe influenza have been identified as age,
with individuals at the extreme of age at higher risk, other
underlying co-morbidities such as obesity, heart disease also
elevate the risk of poor clinical outcomes [2]. Although the
mechanisms that trigger these complications of influenza are
poorly understood a combination of viral virulence as well
uncontrolled inflammatory responses to the virus has broadly
been suggested to be a predominant mechanism for severe lung
pathology from influenza [3]. A number of studies have attempted
to unravel the mechanisms contributing to lethality using mouse
models of influenza which replicate many pathological features of
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human pandemics including acute immune responses, inflamma-
tory lung damage and potentially fatal pneumonia [4,5]. Recent
reports have employed systems biology approaches to indicate that
lethality in mice may be primarily driven by a self-amplifying
inflammatory neutrophil response triggered by the virus [6].
Similar studies in more relevant human cohorts are significantly
limited both by lack of accurate methods to measure acute lung
injury and the large variations in individual response to the viral
infections. Several studies have examined correlation of disease
parameters such as viral shedding and symptom scores with levels
of IL-6 [7,8], an acute phase cytokine which was recently reported
as a potential biomarker of severity in pandemic influenza
infections [9]. While providing important insights into potential
determinants of pathology in humans, these markers have limited
specificity and are unable to inform on specific lung injuries
relevant to influenza infection in a clinical setting. Notwithstand-
ing the diverse factors that result in severe outcomes in influenza
patients, it is generally recognized that management of disease
severity in influenza is greatly improved by early detection and
treatment.
Development of biomarkers that can model one or more
features of disease severity can additionally be expected to
facilitate early prediction and therefore treatment. In this report,
we have attempted to bridge the gap between mouse and human
influenza infections. Through comprehensive molecular analysis of
sera and bronchoalveolar lavage (BAL) from a mouse model of
influenza, as well as a longitudinal cohort of influenza patients, we
have identified molecular markers of disease progression of
influenza that may translate to clinically useful markers of
infection-induced lung injury in humans.
Methods
The mouse model of influenza infection
C57BL/6 (B6) mice at 8–12 weeks of age were purchased from
the Centre for Animal Resources (CARE), Singapore. Influenza
A/Puerto Rico/8/34 H1N1 virus (PR8) were provided by
Professor Vincent TK Chow (National University of Singapore,
Singapore). Mice were infected with a sub-lethal dose of influenza
virus by intra-tracheal administration after anesthetization. At
indicated time points mice were euthanized and sera were
collected. BAL was performed using 1 ml sterilized PBS for
3 times per mouse, the collected fluids were pooled. The BAL
fluids were centrifuged at 5,0006g for 10 min and the superna-
tants were frozen at 280 deg.
This study was carried out in strict accordance with the
National Advisory Committee for Laboratory Animal Research
(NACLAR) Guidelines (Guidelines on the Care and Use of
Animals for Scientific Purposes) in facilities licensed by the Agri-
Food and Veterinary Authority of Singapore (AVA), the
regulatory body of the Singapore Animals and Birds Act. The
protocol was approved by the Institutional Animal Care and Use
Committee (IACUC), National University of Singapore. Mice
were monitored every day after injury. At different time points, a
group of mice were euthanatized by injection of ketamine/
meditomidine, the lung samples were then collected for experi-
ments. Any mouse with 30% body weight loss will be euthanatized
immediately.
Influenza patient recruitment, sample collection and
clinical evaluation
The early dengue infection and outcome (EDEN) study is a
multi-center longitudinal study of adult febrile infections that was
carried out at a number of clinics island-wide in Singapore [10].
As the main inclusion criteria in this study was fever, over 20% of
the patients enrolled were eventually found to be negative for
dengue but positive for influenza A virus.Enrollment of eligible
individuals was based on written informed consents and the
protocols were approved by the National Healthcare Group
(DSRB B/05/013). The study protocols for the study have been
described earlier [10]. In brief, adult patients (.21 years)
presenting with acute onset fever ($38.0uC for less than 72 hours)
without rhinitis were included in the study. NP swabs collected
were tested for viral pathogens by direct immunofluorescence
assay (DFA) and virus isolation using R-MixTM cells in shell vials
(Diagnostic Hybrids Inc., Athens, Ohio) according to the
manufacturer’s instructions. The D3 Ultra DFA Respiratory Virus
Screening and ID Kit (Diagnostic Hybrids Inc., Athens, Ohio) to
detect for influenza A and B, RSV, human metapneumovirus,
adenovirus, and parainfluenza 1, 2 and 3 in both DFA as well as
shell vial cultures.Subtyping of influenza A virus was carried out
by RT-PCR usingpreviously published protocols [11,12]. Venous
blood samples were also collected at enrolment (visit-1) as well as
on fever day 4 to 7 (visit-2) and weeks 3 to 4 (visit-3), aliquoted and
frozen at 280uC. ‘Fever day’ here refers to number of days post
onset of fever.
Fluorescent bead-based measurement of cytokines
Cytokine measurements were performed in duplicates using
either the Bioplex 23-plex mouse cytokine kit or the Bioplex 27-
plex human cytokine kit from BioRad as per manufacturer’s
instructions. For mouse BAL fluid analysis, undiluted BAL was
mixed with 20% BSA to a final concentration of 1% before use in
the bioplex assay.
For human serum samples, 12.5 uL of serum was used for each
measurement. The standard curves were optimized automatically
by the software (Bioplex manager) and verified manually. The
Bioplex manager software was used to calculate cytokine
concentrations and only measurements that showed a coefficient
of variability (CV) of ,10% were included for further analysis.
Levels of most cytokines were below detection limit in BAL
obtained from Day-0 infected mice as well as in some of the late
time points. For the purpose of analysis the values here were set to
the lower limit of detection in each case.
Quantitative analysis of mouse BAL proteome
Sample pooling, iTRAQ labeling and OFFGEL peptide
separation. We performed an isobaric tagging for accurate
quantitation (iTRAQ) method for multiplexed proteomic analysis
of BAL fluid from infected mice. For this, BAL fluid samples from
3mice each at Days 0, 5, 14 and 21 were concentrated and the
protein concentration was measured in each sample using the
BCA method in a kit (Pierce chemical co. USA). Seventy-five
micrograms of protein was subjected with trypsin digestion at a
ratio of 1:80 (trypsin: protein) followed by labeling with isobaric
tags using the 4-plex-iTRAQ kit (AB Sciex Pte Ltd, USA) as per
manufacturer’s instructions. The peptides from Day-5 were
labeled with 115 reporter ions while those from Days 14 and 21
were labeled with 116 and 117 reported ions. Peptides from Day-0
were labeled with 114 reporter ion which served as a reference
control. The individually labeled peptide samples from each group
were pooled and multiplexed peptide samples were desalted using
a C-18 SPE cartridge (Agilent technologies), resolved by isoelectric
focusing on a pH3–10 strip (GE healthcare) on an OFFGEL
fractionator (Agilent technologies). The resolved peptides were
collected in 12 fractions, dried and dissolved in 15 ml of 2%ACN/
0.1%TFA.
Serum Markers of Influenza-Induced Lung Injury
PLOS ONE | www.plosone.org 2 February 2014 | Volume 9 | Issue 2 | e86912
LC MS/MS analysis. The samples were analyzed on an
Agilent 6520 Accurate-mass QTOF-LC/MS system equipped
with a 1200 series HPLC-Chip/MS system. We separated
peptides on a HPLC-Chip with 75 um X 150 mm analytical
column HPLC-Chip and a 160 nL enrichment column. Three
injections (1 ul each with approximately 2 ug peptides) of each
sample were separated using a 60 min gradient (5% at 0 min 10%
2 min, 50% 42 min 80% 42–50 min, 5% 50–60 min) with
Water/0.1%formic acid as aqueous phase and 95%acetonitrile/
5%water/0.1%formic acid as organic phase at flow rates of
300 nL/min. Peptides eluting from the LC were injected online
into the accurate-mass QTOF and examined in positive ion mode
with the following settings for MS mode: 4 spectra/sec, m/z 110–
2300, MS/MS mode: 8 spectra/sec, m/z 60–1097 with drying gas
flow 5 L/min, 325 degC, collision energy slope 3, intercept 2.5,
and a capillary voltage of 1950.
Data analysis. Spectrum Mill software (Agilent Technolo-
gies) was used for protein identification and quantitation of
iTRAQ reporter ion intensities. A minimum peptide score of 8
and a protein score of 10 was used to generate protein lists by
searching against the Swissprot database. These thresholds were
determined by comparing results from searching the Swissprot
database and a reversed random database to identify error rates.
The peptide and protein score thresholds indicated above
ensured a false discovery rate of ,5% in protein identification.
Only proteins identified with two or more peptides were selected
for relative quantification. A global weighted threshold for fold
change was determined by comparing the ratio of summed
intensities of each reporter ions for all peptides (115/114 1.13;
116/114- 1.19; 117/114- 0.91) and then the intensities of each
peptide ratio were further corrected by this factor. This weighted
threshold was essential to make sure the fold changes observed
were not simply due to an overall bias towards one or more
reporter ion. Finally, fold change for each protein was calculated
as a ratio of summed intensities of reporter ion across different
peptides per protein. Further, a background range for fold
changes was determined by average of ratios of test samples
(Days 5, 14 and 21) and control (Day 0) and was found to range
between 0.7–2.1. Therefore for the final shortlist of candidates
we employed a more conservative fold change range of 0.6 for
down regulation and .=3 for upregulation in relation to
controls.
Measurement of lung proteins in Mouse BAL and in
patient sera
Lung proteins CC10, SPAB, SPC and SPD were detected in
mouse BAL and serum samples by western blotting. Briefly,
10 ug of normalized BAL samples from Days-0, 5, 14 and 21
were separated on a 4–15% SDS-PAGE, transferred to a
nitrocellulose membrane and probed with mouse-specific anti-
bodies antibodies to CC10 (Santa Cruz, SC-9772), SPA (Santa
Cruz, SC-13977), SPB (Santa Cruz, SC-133143), and SPD
(Santa Cruz, SC-13980). Measurement of SPA and CC10 levels
in human sera was performed by ELISA using commercially
available kits specific for human SPA (Biovendor Research and
Diagnostic products; SPA-RD191139200R; CC10-
RD191022200)) according to manufacturer’s instructions. For
measurements of SPA serum samples were diluted 10 fold while
for CC10 a 25 fold dilution was used.
Measurement of serum chlorotyrosine and nitrotyrosine
Nitrotyrosine (NT) and chlorotyrosine (CT) in mouse and
human serum were measured by a Liquid chromatography-triple
quadrupole MS method we have previously described [13].
Briefly, 2 mg of serum protein was spiked with 4 pmol internal
standards (IS) L-3-chloro-[13C9, 15N]-tyrosine and L-3-nitro-
[13C9, 15N]-tyrosine, and digested in the sodium acetate solution
0.1 M (pH 7.4) with 0.4 mg pronase E (freshly treated by the size-
exclusive micro bio-spin column). The mixture was incubated at
50uC for overnight (16 hrs.) and filtered by Vivospin500 3KMW
centrifuge filter at 15,000 rpm to remove undigested protein. The
amino acids were further purified by Agilent 1200 series HPLC
system (Waldbronn, Germany) on an Xbridge TM Phenyl column
(3.5 mm, 4.6650 mm, Waters, Milford, MA). The fractions
containing nitrotyrosine and chlorotyrosine, together with internal
standards, were collected and dried by SpeedVac for subsequent
LC/MS/MS analysis. Subsequent mass spectrometry analysis of
target compounds involved separation on an Xbridge TM Phenyl
column (3.5 mm, 1.06100 mm, Waters, Milford, MA) online
injection into an Agilent 6460 triple quadrupole mass spectrom-
eter. Two microliters of each sample was injected and eluted by
isocratic 25% methanol (0.1% formic acid) for 13 min at 15 mL/
min. CT along with IS were analyzed by regular multiple reaction
monitoring (MRM) as follows: 216/170 (CT) and 226/179 (CT,
IS). NT along with IS were measured by modified MS3 based in-
source fragmentation as follows: 181/117 (NT) and 190/125 (NT-
IS) by elevating the potential to 135V at the ion source. The limits
of quantitation achieved were 8.1 and 7.3 nM for CT and NT,
respectively.
Statistical analysis
K-means clustering was performed on time courses of
measurements using the Unscrambler-X statistical software
package (CAMO software, Oslo, Norway). In order to perform
K-means clustering of time courses of cytokines levels over
different time points, cytokines levels were first normalized across
the three time points by dividing the values by the means across
the time points. It was empirically found that K= 4 gives the best
inter-class variances. In a second step, the members across
different clusters were compared manually to determine if the
fold changes of cytokines levels between visit 1 and 2, and visit 2
and 3 were statistically significant (p,0.05); if not, the clusters
were merged. This resulted in three broad clusters as shown in
the results section. The Willcoxon rank sum test was used for
estimating the significance of differences between population
means. In general p,0.05 was considered significant. Correlation
analysis was performed using the Pearson’s correlation matrix on
the Graphpad prism software and where indicated, the
correlation coefficient and the significance values are reported.
ROC curves were generated using Graphpad prism software.
Results
I. Cytokines and protein adducts identify distinct disease
states in a mouse influenza model
A detailed measurement of levels of 23 cytokines in the BAL,
at 2-day intervals between days-0 to 25 revealed maximal
elevation of inflammatory cytokines IL1a, IL1b, IL6, TNFa,
IFNcas well as chemokines mKC, Eotaxin, MIP1a, MIP1b and
MCP1 during the days 5–9 of infection (Fig-1A & Fig-S1). BAL
protein concentration has been extensively used as an indirect
though crude measure of lung inflammation [14]. In our mouse
model, the total BAL protein concentration increased signifi-
cantly to peak at day-14 and by day-21 the levels decreased by 5-
fold, consistent with maximal lung damage and recovery during
these stages respectively (Fig 1-B). Protein adducts formed from
nitric oxide chemistry have emerged as sensitive indicators of
neutrophil and macrophage activity [15]. We measured levels of
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two protein adducts 3-chlorotyrosine (CT) and 3-nitrotyrosine
(NT), in sera from infected mice at days-0, 5, 14 and 21, using a
mass spectrometry-based method. Compared to controls, serum
NT levels were maximally elevated at day-5 (Fig-1C). In contrast,
levels of serum CT were increased significantly between days 5
and 14 and appeared to rapidly decrease at day-21 (Fig-1D). The
overall accumulation of CT adducts at day-14 is consistent with
maximal neutrophil infiltration during this stage (data not
shown). Together, the above data as well as previously published
information on this model [16] established the kinetics of viral
replication and clearance, inflammatory lung damage as well as
recovery in our non-lethal mouse model of infection with
influenza virus PR8 strain.
II. Proteomic analysis of mouse BAL during influenza
infection
We performed an iTRAQ based quantitative proteomic
analysis of BAL from mice infected with influenza for different
lengths of time. In particular, we evaluated stages we have shown
to correlate with peak viremia, inflammatory lung damage and
recovery of lung function both in this study, and in previous
reports [16,17]. From the iTRAQ analysis we identified a total of
113 proteins, of which 42 satisfied our filtering criteria of proteins
that exhibited fold changes .=3 or ,=0.6, compared with
control, were identified with 2 or more peptides, and were not
immunoglobulin components (Table-1). A K-means clustering
analysis identified overall four distinct clusters whose levels
changed differently across different stages of disease (Fig-2A).
Cluster-1 consisted of 5 proteins that were maximally elevated at
day-5 and remained elevated at day-14, returning to near control
levels by day-21. These included a majority of acute phase
reactants and complement proteins. Cluster-2 consisted of 7
proteins that were maximally elevated during day-14, a stage
coinciding with peak neutrophil infiltration and lung damage.
These consisted of several iron-binding proteins, complement
proteins, and hemoglobin isoforms indicative of a significant
increase in vascular permeability resulting in global influx of
serum proteins. Cluster-4 consisted of 21 proteins that were
elevated to a lesser extent in Day-5 and remained elevated
through all stages. A separate cluster of proteins, Cluster-3, was
observed consisting of 9 proteins that were progressively depleted
from days-5 and 14 with some returning to control levels by day-
21. Interestingly this cluster consisted of mostly resident BAL
protein such as uteroglobin/CC10, Surfactants SPA, SPB, SPD,
glutathione S-transferase isoform omega-1, lysozyme C2. It is
noteworthy that among proteins identified by single peptide hits
(Supplementary Table S1), several proteins of analogous function
to the above, such as glutathione S-transferase isoform-1, Cu-Zn
superoxide dismutase, were also depleted indicating that possibly
a broader range of resident BAL proteins are depleted during
acute and inflammatory stages of influenza infection. Immuno-
blot analysis of CC10 confirmed its reversible depletion from
BAL during days-5 and 14 (Fig-2B). Interestingly, when we
examined in parallel sera from the same mice we found an
inverse profile wherein the CC10 that is normally absent or
undetectable in sera, reversibly increased to a detectable level at
day-5 and day-14 (Fig-2B). A similar profile in serum was
observed for several surfactant proteins as seen by immunoblots
(Fig-2B). Overall, a significant number of BAL proteins were
Figure 1. Stages of disease progression in mice infected with influenza virus. A. Changes in inflammatory BAL cytokines and chemokines
measured at 2-day interval till day 22 post infection. The Y-axis shows cytokine levels that have been normalized by dividing with mean. B. total
protein content of the BAL during influenza infection in mice. C. Levels of CT in mouse serum displayed as pg per milligram of protein. D. Levels of NT
in mouse serum displayed as pg per milligram of protein. Statistical confidence measure using Mann Whitney test with p values 0.05 (*), 0.005 (***)
indicated on the box plot.
doi:10.1371/journal.pone.0086912.g001
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identified whose levels changed dramatically around the time
during the time of maximal lung inflammation.
III. Establishing kinetics of disease progression in a
longitudinal cohort of influenza patients
Our experiments in mice indicated that influenza infection
results in leakage of lung BAL proteins into the blood. Because
loss of vascular permeability has been suggested to be one of
the pathological features of severe influenza, we examined if the
related leakage of lung surfactant proteins into serum was a
more universal feature observable also in humans infected with
the influenza virus. For this, we obtained serum samples from a
longitudinal cohort of patients infected with two co-circulating
strains of influenza virus- H1N1pdm09 and H3N2. These
patients were recruited as part of the EDEN study where
patients diagnosed with influenza were followed up at 48–
72 hours (early febrile, Visit-1), 4–7 days and 3–4 weeks post
onset of febrile symptoms and blood samples collected at these
three stages from each sample [10]. The characteristics of
patients selected for our study are indicated in Table-2.
Although the longitudinal nature of this cohort allowed us to
evaluate disease progression analogous to that in mice, direct
comparison of disease progression in mouse and human models
is complicated by several factors including- 1) qualitatively and
quantitatively different immune responses to the virus, 2)
different viral loads as well as replication kinetics. Therefore
as a first step we performed a detailed evaluation of cytokines
and protein adducts in our patient population to establish
broadly the stages indicative of inflammation and antiviral
responses. We measured 23 cytokines using a multiplex kit as
described in methods and performed a K-means clustering
analysis across the different visits to identify common signatures
(Fig-3A). In patient group infected with seasonal H3N2 strain,
Cytokines and chemokines including IP-10, IL-b, IL-1ra, IL-6,
IL-9, IL-10, IL-17, VEGF and MCP1 were maximally elevated
during the early febrile phase returning to basal levels by visit-2
and formed one cluster. IP-10 was the most significantly
elevated cytokine, increasing to .50fold at visit-1 and dropping
to control levels by visit-2 (Fig-S2). A second group of cytokines
including IL-7, Eotaxin, G-CSF, IFN-g and MIP-1b increased
to a maximal level during visit-1 but remained at high during
the subsequent visits. A third cluster of cytokines such as PDGF-
b, IL-4, IL-8 and IL-12 remained at maximal level from Visits
1–3. Interestingly, a similar analysis on patient group infected
with H1N1pdm09indicated that, while majority of cytokines
clustered similar to the seasonal flu patients, a distinct group of
cytokines including IL-1b, IL-9, IL-17 and VEGF clustered
differently. A closer look at individual cytokines revealed specific
differences in these as well as four other cytokines, IL-4, IL-6,
IL-8, G-CSF in the two patient groups. With the exception of
IL-4, all other cytokines were elevated in patients with seasonal
flu compared with H1N1pdm09 during visit-1 (Fig 3-C–F). We
next measured the levels of CT and NT in serum samples
patients with H3N2 (n= 15) and H1N1 (n= 16) and found CT
to be maximally elevated at visit-1 reducing significantly during
visits 2 and 3 (Fig-3G). NT on the other hand showed highest
levels during Visit-2 although the differences between the
various time points were not statistically significant (Fig-3H).
Overall, cytokine and protein adduct profile observed during
the 48–72 hours post onset of fever (visit-1) in human patients
appears analogous to the day-14 infection in our mouse model
described in the previous section.
IV. Lung surfactant proteins in sera of humans infected
with the influenza virus
To test the hypothesis that appearance of lung proteins in the
blood during influenza may be a universal feature of the
disease, we measured the levels of two BAL proteins- CC10 and
surfactant protein A (SPA) in influenza patient sera using
commercial ELISA kits. CC10 levels in serum were significantly
higher (Fig-4A) in the influenza patients during the febrile stage
(visit-1) compared with convalescence (Visit-3). A similar profile
was observed for SPA which was elevated nearly 40 fold in
Visit-1 compared to Visit-3 (Fig-4B). Maximal elevation of these
proteins at visit-1 is consistent with the peak of inflammation
during this period. Increased vascular permeability is an
established feature of acute lung injury and disease severity in
viral infections [18,19]. The increase in SPA or CC10 levels in
influenza patients with seasonal Flu was indistinguishable from
those with H1N1pdm09 (Fig-4A–B). A receiver operator
characteristics (ROC) curve analysis of SPA and CC10 in
classifying patients with acute infection from convalescent states
Figure 2. Dynamics of BAL proteome at different stages of influenza infection. A. K-means cluster analysis of proteins that exhibited
significant fold change across Days 5, 14 and 21 when compared with Day-0 of influenza infection. The Y-axis indicates a weighted value that is the
individual value divided by mean across the four time stages. B. Immunoblot analysis of mouse BAL and serum to evaluate levels of selected lung
proteins that were depleted from BAL during peak viraemia and inflammation.
doi:10.1371/journal.pone.0086912.g002
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indicated excellent performance for both SPA (AUC 1.0,
p,0.0001) than CC10 (AUC 0.971, p,0.05) (Fig-4C–D). We
next evaluated the potential of using serum levels of lung
surfactant proteins as a predictor of disease severity. Because
none of the patients in our influenza cohort were hospitalized
with severe illness we used duration of illness, reported by the
patients, as a measure of disease severity. We classified patients
with symptoms lasting 5 days or less as mild disease and those
Table 1. BAL proteome flux in a non-lethal mouse model of influenza infection.
BAL Protein Swissprot No.of Fold Change over Day-0 Cluster
Accession peptides Day-5 Day-14 Day-21 Group*
Serum albumin P07724 31 5.32 6.79 4.41 4
Serotransferrin Q921I1 28 7.22 11.41 8.48 4
Complement C3 P01027 28 3.83 3.07 1.65 4
Hemopexin Q91X72 16 3.34 5.54 2.16 4
Alpha-2-macroglobulin Q61838 14 5.72 5.34 2.45 4
Ceruloplasmin Q61147 14 2.65 4.45 2.45 4
Vitamin D-binding protein P21614 12 4.34 5.12 2.48 4
Apolipoprotein A-IV P06728 10 2.79 4.47 2.58 4
Liver carboxylesterase N P23953 9 2.18 3.16 1.94 4
Fibronectin P11276 9 2.41 6.95 4.77 2
Apolipoprotein A-I Q00623 8 4.03 4.57 2.47 4
Haptoglobin Q61646 8 26.86 4.24 9.09 1
Kininogen-1 O08677 7 3.2 4.85 2.8 4
Antithrombin-III P32261 7 1.93 3.21 2.21 4
Hemoglobin subunit alpha P01942 5 0.81 4.93 1.14 2
Beta-2-glycoprotein 1 Q01339 6 3.77 6.13 3.07 4
Chitinase-3-like protein 3 Q35744 6 0.48 0.49 1.45 3
Murinoglobulin-1 P28665 5 4.3 4.9 2.46 4
Gelsolin P13020 5 2.03 14.11 4.47 2
Actin, cytoplasmic 2 P63260 6 3.67 3.15 1.36 4
Alpha-2-HS-glycoprotein P29699 5 2.25 3.07 1.87 4
Hemoglobin subunit beta-1 P02088 4 0.92 5.07 1.74 2
Clusterin Q06890 4 3.55 3.55 2.29 4
Plasminogen P20918 4 2.97 3.45 3.1 4
Pulmonary surfactant-associated protein D P50404 4 0.6 0.55 1.2 3
Uteroglobin Q06318 3 0.2 0.13 0.4 3
Chitinase-3-like protein 1 Q61362 3 22.03 11.23 5.2 1
Pulmonary surfactant-associated protein B P50405 3 0.56 0.3 0.49 3
Afamin Q89020 3 2.56 4.43 2.13 4
Fibrinogen beta chain Q8K0E8 3 5.87 4.6 1.68 1
Complement factor B P04186 3 3.52 3.54 2.25 4
Glutathione S-transferase omega-1 P78417 3 0.23 0.27 0.91 3
Apolipoprotein E P08226 3 1.78 6.24 3.45 2
Lysozyme C-2 P08905 3 0.53 0.41 0.77 3
Complement C4-B P01029 3 3.6 2.63 1.63 1
Selenium-binding protein 2 Q63836 3 0.54 0.57 0.76 3
Complement factor H P06909 3 4.33 9.32 1.7 2
Vomeromodulin Q80X17 2 0.56 1.2 4.29 3
Fetuin-B Q9QXC1 2 1.63 3.73 1.19 2
Inter-alpha-trypsin inhibitor heavy chain Q61703 2 2.45 4.31 1.85 4
Lactotransferrin P08071 2 3.09 1.69 2.09 1
Pulmonary surfactant-associated protein A P35242 2 0.49 0.29 0.59 3
*Cluster grouping based on K-means clustering described in methods. # Days post infection.:
doi:10.1371/journal.pone.0086912.t001
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with symptoms lasting greater than 5 days as severe or
prolonged illness disease. The ROC curve analysis indicated
an overall poor classification for the two proteins with a
marginally improved performance for SPA (AUC 0.615, p 0.29)
compared with CC10 (AUC 0.537, p 0.7) (Fig-4C–D). We
observed marginal (r.0.6) but highly significant (p,0.001)
correlation between SPA and cytokines such as IL-6, PDBF-BB
and duration of symptom.
Figure 3. Molecular tracking of disease progression in a human cohort of influenza patients. K-means cluster analysis of cytokines
measured in sera of influenza patients at three stages of infection as indicated. Average profile of changes in each luster (A) as well as list of cytokines
in each cluster as indicated. Changes in a selected list of cytokines including IL1b (C), IL6 (D), IL-8 (E), IL4 (F). Levels are indicated as picogram per ml of
serum. Levels of protein adducts 3-chlorotyrosine (CT) (G), and 3-nitrotyrosine (H) shown as picogram per milligram protein. Statistical confidence
measure using Mann Whitney test with p values 0.05 (*), 0.005 (***).
doi:10.1371/journal.pone.0086912.g003
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Discussion
The underlying mechanisms that accompany the widely varied
human responses to influenza virus infections are not fully
understood. We have conducted a systematic study of influenza
infection centered on a well-established non-lethal mouse model
to help identify early molecular markers of disease severity. The
relevance of using of inbred mouse strains as hosts for
experimental influenza infections has been debated and admit-
tedly has the major disadvantage of being unable to model more
complex human immune responses. Nevertheless, mouse models
have been used extensively to understand mechanistic basis of
pathology in influenza and provide the added advantage of
removing the ‘noise’ from multiple underlying conditions and
immune responses that is seen in human disease, and more
suited to uncover universal features of disease pathology.
Kinetics of cytokine production, immune and inflammatory
responses can vary significantly depending on viral dose, time of
measurements etc [20]. Therefore, as a first step we defined stages
of disease progression in our experimental mouse model by
tracking the BAL cytokine flux as a measure of the early and late
immune response up to 25 days post virus inoculation. Consistent
Table 2. Characteristics of Influenza patient study population.
Patient Groups Virus strain Age Race Blood sampling Time *
Influenza Seasonal Flu 37616.54 Chinese 56.2% 30616 hours (visit-1)
(n = 26) (H3N2) Indian 6.2% 88640 hours (Vist-2)
2007–2010 Malay 25.0% 1466 days (visit-3)
Others 12.5%
Influenza H1N1 pdm09 2569.66 Chinese 53.8% 23622 hours (visit-1)
(n = 30) 2009–2010 Indian 15.2% 108640 hours (Visit-2)
Malay 15.6% 1563 days (visit-3)
Others 15.5%
*Average 6 SD time from fever to phlebotomy (visit-1), between visits 1 & 2 (visit-2) and between.
visits 2 & 3 (visit-3).
doi:10.1371/journal.pone.0086912.t002
Figure 4. Serum levels of lung BAL proteins, CC10 and surfactant protein-A in human influenza patients. Levels of CC10 (A) and
surfactant protein A (B) were measured in sera from human influenza patients using commercial ELISA kits as described in methods. The levels are
indicated as ng/ml of serum and were compared with the levels measured in convalescent sera from the same group of individuals. An ROC curve
analysis of each of the proteins indicated different association of these proteins with – Acute versus convalescent stages of disease (solid line) or with
mild or severe disease (dashed line). Statistical confidence measure using Mann Whitney test with p values 0.05 (*), 0.005 (***).
doi:10.1371/journal.pone.0086912.g004
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with analogous reports in literature [20,21], we observed sharp
elevation of cytokines related to antiviral and innate immune
pathways, as well as chemokines peaked around day-5 and
correlated with drop in viral titers. Cytokine analysis of a human
influenza cohort also revealed a sharp elevation of cytokines
during the acute febrile phase of infection. However in the human
cohort the fold increases in cytokine levels was more modest and
the temporal cytokine flux was more complex. Although the
significant differences in types and clinical characteristics of
cohorts reported in literature prevented direct comparison of our
results, elevation of inflammatory cytokines and chemokines early
during presentation, and the levels we have observed, are
consistent with reports in literature [22,23,24]. Additionally, some
of these differences could also be attributed to different immune
response to different viral strains. For example, levels of
inflammatory cytokines IL-1b and IL-6 were greater in patients
with H3N2 seasonal flu infections as compared to H1N1pdm09
strains. Nitrating oxidants play an important role in immune
defense against pathogens where peroxidases such as myeloper-
oxidase can use reactive nitrogen species to form protein adducts
such as CT and NT [15]. Neutrophils have been demonstrated to
use the Myeloperoxidase-H2O2-NO22 system to nitrate and
chlorinate tyrosines on proteins [25]. In contrast to the short-lived
reactive species, CT and NT have a longer half-life in circulation
and consequently extremely useful as indicators of neutrophil
activity. While both levels of both CT and NT rose significantly
during day-5, CT levels continued to rise sharply to peak at Day14
suggesting that neutrophil accumulation and activity continued
well past the viral clearance phase. It is unclear why NT levels at
Day-14 returned to baseline, but could possibly indicate different
sites of accumulation of these two adducts with NT adducts
predominantly localized to lung tissue while CT is more readily
observed in luminal contents such as the BAL. Interestingly, levels
of CT in sera from a human influenza cohort were also much
more sharply elevated than NT and peaked during the acute phase
of infection. Together these results help establish a molecular
description of disease progression in two very disparate systems-
mouse models and a human cohort, setting the stage for detailed
experiments in mouse models aimed at finding markers relevant to
human disease.
We used an iTRAQ approach to quantify changes in BAL
proteome during acute phase, pathological phase as well as
recovery stages relative to mock-infected mice. Several previous
studies have characterized the protein composition of BAL in
mice and humans [14,26] and consistent with these studies we
observed that plasma proteins were the most abundant compo-
nents of the BAL presumably via diffusion across the vascular
barrier. We focused on identifying changes in BAL protein
composition that correlate with disease progression and not
surprisingly observed significant changes in more than 30
proteins correlating with acute and inflammatory phases of
infection. Levels of acute phase reactants and complement
proteins were significantly elevated during the acute and
inflammation phases of the infection while by day-21 the levels
resembled mock infected animals. Inflammation-induced loss of
vascular permeability in the lungs is common in viral infections
[18] and explains to a large extent the influx of plasma proteins
into the BAL. Interestingly, the kinetics of protein flux we
observed indicated that there was some specificity to the process
with some proteins changing earlier than the others. Accumu-
lation of hemoglobin, occurred only at day-14, later than acute
phase response perhaps indicating that subtle influx of specific
plasma proteins into the BAL precede a more dramatic global
influx during peak inflammatory tissue damage event. The
possibility that some of these proteins could be early markers of
lung damage remains to be tested, although invasive nature of
BAL collection procedures makes the specific use of plasma
proteins in the BAL as a clinically useful marker for lung damage
untenable. More interesting from a biomarker perspective was
our observation that a subset of locally produced BAL proteins
was depleted from the BAL during stages corresponding to the
acute and inflammatory stages of disease. Several surfactant
proteins including SPA, SPD and SPB as well as cc10 a lung
clara cell specific protein, glutathione S-transferase and lysozyme
were depleted from the BAL accompanied by their appearance
in the serum in quantities detectable by western blotting.
A well-documented pathological feature of acute lung injury is
the disruption of the capillary endothelial barrier, resulting
leakage of blood proteins into lung space and vice versa [27].
The appearance in plasma of proteins specific to the lung
epithelium has been previously suggested to indicate loss of this
barrier. Levels of lung surfactant proteins in serum have been
reported to be elevated in response to pulmonary stress such as
seen in COPD [28], pulmonary fibrosis [29] as well as in
bacterial pneumonia [30]. Pulmonary surfactants are small
phospholipoproteins that have been associated with diverse
functions including, maintenance of alveolar function, innate
immune defense especially in bacterial infections and are among
the most abundant locally produced proteins in the BAL [31].
Our observation of a depletion of surfactant proteins from the
murine BAL concomitant with their appearance in the serum is
indicative of a ‘leakage’ of these lung proteins, presumably
related to lung pathology caused by the influenza virus. To our
knowledge this is the first report of BAL protein leakage into
serum in influenza infections and raised the possibility of using
this as a means of detecting lung injury in acute influenza
infections. We tested this in a cohort of influenza and determined
that significant amounts of at least two surfactants SPA and
CC10 were detected in sera specifically during the acute febrile
stage of infection. ROC curve analysis suggests that SPA had a
significantly high predictive power in distinguishing influenza
patients from asymptomatic controls. Levels of SPA also
correlated with IL-6, which has been proposed as a marker for
inflammatory damage in influenza. Although IL-6 levels were
higher in our seasonal flu (H3N2) cohort, this was not statistically
significant likely due to limited statistical power of this small
cohort. Together, these observations suggest that specific lung
proteins such as SPA have the potential to serve as tissue specific
markers of lung damage in viral infections such as influenza. We
also hypothesize that leakage of surfactants into the serum
accompanies most influenza episodes, and may be proportional
to the severity of lung damage. Use of more sensitive methods of
detection of these proteins in the serum may facilitate earlier
determination of lung damage especially in the context of severe
influenza infections. Admittedly, clinical value of these markers in
early detection of severe disease remains to be tested in patients
with established severe lung pathology that were absent from the
cohorts evaluated here. Establishing specificity of these markers
to influenza, as well as statistical power of their performance will
require follow up studies in larger and more diverse clinical
cohorts. In conclusion, this study demonstrates that a subset of
lung proteins may have tremendous potential as predictive
biomarkers in severe influenza that will be improved by
development of additional tools for high sensitivity measurement
of these proteins in human sera.
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Supporting Information
Figure S1 Temporal profile of BAL Cytokines in influ-
enza infections. Cytokines levels in BAL were measured as
described in methods at indicated days following infection with
PR8 influenza strains. The data is plotted as nanogram per ml and
is shown as mean of data from 3 mice per group.
(TIF)
Figure S2 Temporal serum cytokine profile in a human
cohort of influenza patients. Cytokine levels were measured
in sera from two groups of human influenza cohort- one with
influenza strain H3N2 (n= 26) and second infected with 2009
H1N1pdm09 virus strain (n = 30) as described in methods. In
addition a separate cohort of asymptomatic healthy individuals is
also shown as controls.
(TIF)
Table S1 BAL Proteome flux in mouse model of
infection- single peptide matches.
(DOCX)
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